Andrew Cheng Sells 24,992 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO) Stock

Akero Therapeutics, Inc. (NASDAQ:AKRO) CEO Andrew Cheng sold 24,992 shares of the company’s stock in a transaction dated Wednesday, October 16th. The shares were sold at an average price of $31.14, for a total transaction of $778,250.88. Following the completion of the sale, the chief executive officer now directly owns 605,417 shares of the company’s stock, valued at $18,852,685.38. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink.

Andrew Cheng also recently made the following trade(s):

• On Friday, October 18th, Andrew Cheng sold 63,539 shares of Akero Therapeutics stock. The shares were sold at an average price of $31.53, for a total transaction of $2,003,384.67.
• On Tuesday, September 10th, Andrew Cheng sold 1,738 shares of Akero Therapeutics stock. The shares were sold at an average price of $26.18, for a total transaction of $45,500.84.

Akero Therapeutics Price Performance

AKRO traded up $0.41 on Friday, hitting $31.23. 484,151 shares of the company were exchanged, compared to its average volume of 892,003. The company has a debt-to-equity ratio of 0.04, a quick ratio of 24.89 and a current ratio of 24.89. The business’s fifty day moving average is $27.36 and its 200 day moving average is $24.24. Akero Therapeutics, Inc. has a fifty-two week low of $11.25 and a fifty-two week high of $37.00. The firm has a market capitalization of $2.16 billion, a P/E ratio of -9.76 and a beta of -0.25.

Akero Therapeutics (NASDAQ:AKRO) last issued its earnings results on Friday, August 9th. The company reported ($0.81) earnings per share for the quarter, topping the consensus estimate of ($0.90) by $0.09. As a group, sell-side analysts anticipate that Akero Therapeutics, Inc. will post -3.64 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently issued reports on AKRO. HC Wainwright reiterated a “buy” rating and set a $50.00 price target on shares of Akero Therapeutics in a research note on Tuesday, September 17th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Akero Therapeutics in a research note on Thursday, June 20th. One analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, Akero Therapeutics presently has an average rating of “Moderate Buy” and a consensus price target of $43.20.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Russell Investments Group Ltd. grew its position in Akero Therapeutics by 2,366.0% during the first quarter. Russell Investments Group Ltd. now owns 1,233 shares of the company’s stock worth $31,000 after buying an additional 1,183 shares during the period. Headlands Technologies LLC grew its position in shares of Akero Therapeutics by 253.5% in the first quarter. Headlands Technologies LLC now owns 4,217 shares of the company’s stock valued at $107,000 after purchasing an additional 3,024 shares during the last quarter. Ameritas Investment Partners Inc. grew its position in shares of Akero Therapeutics by 20.0% in the first quarter. Ameritas Investment Partners Inc. now owns 6,175 shares of the company’s stock valued at $156,000 after purchasing an additional 1,030 shares during the last quarter. Los Angeles Capital Management LLC acquired a new stake in shares of Akero Therapeutics in the first quarter valued at approximately $211,000. Finally, Quattro Financial Advisors LLC grew its position in shares of Akero Therapeutics by 43,378.3% in the first quarter. Quattro Financial Advisors LLC now owns 10,000 shares of the company’s stock valued at $253,000 after purchasing an additional 9,977 shares during the last quarter.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.